five ligands of the Jagged family and Delta-like family (Jagged 1 and Jagged 2, and Delta-like ligand 1 (DLL1), DLL3 and DLL4). The biochemical details of the canonical Notch signalling cascade have been comprehensively reviewed 2, 3 
. In recent years, evidence has been found of non-canonical Notch signalling that does not require the RBPJ transcriptional mediator complex. These non-canonical signal transduction pathways may occur in the absence of receptor cleavage or through crosstalk with other signalling pathways (including the nuclear factor-κB (NF-κB), transforming growth factor-β (TGFβ) and hypoxia-induced signalling pathways) [4] [5] [6] . Genome-wide expression and chromatin immunoprecipitation (ChIP) studies suggest the existence of a large number of genes that can be regulated by Notch 7, 8 .
Despite the large number of potential Notch target genes, the best-characterized are the basic helix-loophelix (bHLH) transcriptional repressors of the hairy enhancer of split (HES) and hairy-related (HRT) protein families 9 . As Notch signalling is recurrently either used for the generation and development of diverse blood cell lineages or used during peripheral immune responses following pathogenic infections, one of the major challenges is to identify the crucial driver target genes in these different settings in order to better understand how Notch exerts its pleiotropic functions.
The best-studied functions of Notch signalling in haematopoiesis are its essential roles during lymphocyte development, in particular during T cell lineage commitment and maturation in the thymus, and during marginal zone B (MZB) cell development in the spleen. More recently, Notch has also emerged as a key player in dendritic cell (DC) homeostasis and in the development of several lymphocyte subsets belonging to the innate immune system. In this Review, we discuss the role of Notch in the development of these specific blood lineages. Moreover, we highlight recent advances pertaining to Notch signalling in subsets of mature CD4 + and CD8 + T cells in peripheral lymphoid tissues.
Developmental roles for Notch
Notch signalling in T cell and MZB cell development. Bone marrow progenitors seed the thymus via the bloodstream, where they are instructed to adopt a T cell fate and further differentiate into αβ T cells or γδ T cells before emigrating to the periphery. The first insights of Notch function in this context were derived from complementary genetic loss-of-function and gain-of-function studies. Inducible inactivation of Notch 1 or recombination signal binding protein for immunoglobulin κJ region (RBPJ; also known as CSL in humans) in bone marrow progenitors results in a complete block of T cell development, accompanied by the accumulation of ectopic B cells in the thymus 10, 11 . By contrast, the constitutive expression of active forms of Notch induced ectopic T cell development and suppressed B cell development in the bone marrow 12 . Since then, multiple studies, including studies interfering with Notch signalling by transgenic expression of Notch modulators (such as Fringe proteins, Deltex 1 and Notchregulated ankyrin repeat-containing protein (NRARP)) or studies expressing dominant-negative forms of the transcriptional co-activator Mastermind-like protein 1 (MAML1), have confirmed the original findings [13] [14] [15] [16] . This led to a model in which Notch 1 ensures T cell lineage commitment by inhibiting the other multiple cell-fate potentials of thymus-seeding cells, including myeloid cell and B cell potential, as well as conventional DC and plasmacytoid DC potential [17] [18] [19] [20] (FIG. 1) . Although the transcription factor HES1 was recently shown to be an important Notch mediator for T cell lineage commitment, conditional inactivation of HES1 does not lead to the accumulation of B cells or DCs in the thymus 21 . This result suggests that Notch signalling specifies the T cell lineage through the activation of additional downstream target genes.
Although DLL1 and DLL4 can both instruct bone marrow cells to adopt a T cell fate in vitro, genetic ablation studies showed that in vivo the instructive signal is triggered through the interaction of Notch 1-expressing thymus-seeding cells with DLL4-expressing thymic epithelial cells [22] [23] [24] [25] [26] . Notch signalling is highest in immature αβ T cells (including in early thymic progenitors (ETPs), double-negative 2 (DN2) thymocytes and DN3a thymocytes) up to the DN3 stage, at which cells have to pass a critical checkpoint known as β-selection 27 . In these immature thymocytes, Notch 1, but not HES1, is continuously required to restrict developing αβ T cells to the T cell lineage 21 . However, once specified, γδ T cells are less dependent on Notch signalling, at least in the mouse. For human thymocytes the situation seems to be different, as γδ T cells require higher levels of Notch signalling compared with developing αβ T cells 28, 29 . After thymocytes successfully pass β-selection, they immediately downregulate Notch 1 expression, a process that is triggered by the pre-T cell receptor (pre-TCR)-mediated induction of the HLH transcription factor inhibitor of DNA binding 3 (ID3). ID3 inhibits E2A-induced transcription of Notch 1 (REF. 30 ). As a consequence, double-positive (CD4 + CD8 + ) thymocytes have very low levels of Notch signalling, which is presumably required to avoid interfering with positive and negative selection in double-positive thymocytes, as well as to avoid the oncogenic properties of Notch signalling and its targets 8 (FIG. 1) .
Another well-established role for Notch signalling during lymphocyte development is its role in the specification of two different major subsets of splenic B cells, namely MZB cells and follicular zone B cells. Follicular zone B cells participate in T cell-mediated immune responses. These circulating B cells represent the majority of B cells within the spleen, where they localize to B cell follicles, hence the name follicular zone B cells. By contrast, MZB cells are found in the outer region of the splenic white pulp between the marginal sinus and the red pulp 31 . They are important in driving fast and vigorous T cellindependent antibody responses to blood-borne pathogens 32 . Moreover, they express high levels of CD1d, thus allowing them to capture and present lipid antigens to invariant natural killer T cells. Both MZB cells and follicular
Box 1 | A brief overview of Notch signalling
Mammals possess four Notch receptors (Notch 1-4) that are bound by five ligands of the Jagged, and Delta-like family (Jagged 1 and Jagged 2, and Delta-like ligand 1 (DLL1), DLL3 and DLL4). Newly synthesized receptors are proteolytically processed in the Golgi during their transport to the cell surface by a furin-like convertase. This results in the generation of heterodimeric receptors present at the cell surface (see the figure) . Signalling is initiated by ligand binding to the receptors, which subsequently undergo two successive proteolytic cleavages; the first is mediated by disintegrin and metalloproteinase domain-containing protein (ADAM) family metalloproteinases at the extracellular S2 cleavage site close to the transmembrane domain. This results in the shedding of the extracellular part of the receptors, which are endocytosed by the ligand-expressing cell. This process requires monoubiquitylation of the cytoplasmic tail of the ligands by E3 ubiquitin ligases of the Mindbomb and Neuralized families. After a successful S2 cleavage and shedding of the extracellular domain, a last cleavage within the transmembrane domain is triggered by the γ-secretase activity of a presenilin multi-protein complex, thus liberating the Notch intracellular domain (NICD). This is a rate-limiting step during Notch activation, which can be pharmacologically blocked by small-molecule γ-secretase inhibitors 112 . Once the NICD is liberated, it translocates to the nucleus and binds to the transcription factors of the recombination signal binding protein for immunoglobulin κJ region (RBPJ) family (also known as CSL in humans, Suppressor of hairless in Drosophila melanogaster, and LAG-1 in Caenorhabditis elegans). When bound to RBPJ, the NICD recruits additional co-activators, including mastermind proteins (MAML1-3) and p300 in order to induce transcriptional expression of downstream target genes. Furthermore, Notch signalling is regulated at multiple levels. For example, Notch receptors undergo post-translational modifications by Fringe family glycosyltransferases. These transferases add N-acetylglucosamine to O-fucose residues present in certain epidermal growth factor (EGF) repeats of the extracellular domain of Notch receptors 113 . This influences the relative binding avidity of ligand-receptor pairs, which translates into different efficiencies or signalling strength of Notch receptors [114] [115] [116] .
Proteins shown in red are co-repressors of RBPJ; those shown in green are cofactors for RBPJ. Nature Reviews | Immunology 
β-selection
During development, immature double-negative 3 thymocytes have to pass a critical checkpoint known as β-selection, or the pre-T cell receptor (pre-TCR) checkpoint, at which they have to signal via the pre-TCR to continue their development.
Pre-T cell receptor
(Pre-TCR). The pre-TCR consists of a productively re-arranged TCRβ chain associated with CD3 components and an invariant pre-TCRα chain.
Invariant natural killer T cells
These are a specialized subset of innate-like lymphocytes that share properties of both natural killer (NK) cells and T cells. They express NK-related molecules and T cell receptors (TCRs), and their TCRs recognize self and foreign lipids presented on CD1d molecules.
B cells originate from B cell progenitors in the bone marrow. When B cells migrate out of the bone marrow, they colonize secondary lymphoid organs, including the spleen, where they further mature through transitional stages (known as T1 and T2), before ultimately giving rise to mature follicular B cells or MZB cells in the spleen.
The specification process of T2 B cells into either of the two mature B cell fates is influenced by multiple factors 31 . However, conditional gene-targeting experiments of multiple Notch components revealed that the specification of MZB cells is strictly dependent on DLL1-mediated Notch 2 signalling (FIG. 1) . Mice with conditional inactivation of DLL1 or Notch 2 have severely decreased numbers of MZB cells 33, 34 , a phenotype that was also observed in RBPJmutant 35 , MAML1-mutant^^3 6, 37 , Mind bomb 1-mutant^^3 8 and disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) 39 -mutant mice. Taken together, these genetic loss-of-function experiments strongly suggest that this process is mediated via canonical Notch signalling, although, surprisingly, HES1 is not required 21 .
Inactivation of Msx2-interacting protein (MINT; also known as SPEN), which is a negative regulator of Notch signalling, resulted in increased MZB cell numbers 40 , which is an additional confirmation of Notch being an important regulator of MZB cell specification. Moreover, the cooperative action of two Fringe family members (Lunatic fringe and Manic fringe) seems to be necessary to strengthen the presumably weak interaction between MZB cell precursors and DLL1-expressing splenic niche cells 41 . Although it is clear that DLL1 is the non-redundant ligand that triggers a Notch 2 signal to specify MZB cells in the spleen, the nature of the DLL1-expressing cells is still unclear. Although non-haematopoietic cells 33 and, in particular, endothelial cells have been shown to express DLL1 in the red pulp of the spleen 41 , it remains to be shown whether DLL1-expressing endothelial cells are indeed the splenic niche cells that support MZB cell development.
Notch signalling in DC development. DCs are a subset of haematopoietic cells that are specialized in antigen presentation. Until recently the only evidence for Notch involvement in DC differentiation was based on in vitro studies in which DC development could be influenced by the overexpression of Notch receptors or ligands and pharmacological manipulation by Notch inhibitors. More recently, loss-of-function studies have provided conclusive evidence that Notch signalling plays an important part in DC development and homeostasis. Conditional inactivation of RBPJ or Notch 2 specifically in DCs led to a selective reduction of a subset of DCs in the spleen but not in other lymphoid tissues 42, 43 . Splenic DCs comprise a plasmacytoid DC compartment as well as several subsets of conventional DCs that can be identified by their differential expression of CD8 and CD11b, together with their expression of other markers, such as the adhesion molecule endothelial cell-selective adhesion molecule (ESAM). In the absence of Notch 2, only the CD8 − CD11b + ESAM + DC subset was missing, whereas other DC subsets (both conventional and plasmacytoid) were not affected 43 (FIG. 1) . The requirement for Notch 2 in the maintenance of splenic DCs seems to be non-redundant, as conditional inactivation of Notch 1 either in DCs 43 or in all haematopoietic cells 44, 45 does not affect DC numbers. The Notch ligand responsible for directing splenic DC development remains to be identified. However, it is noteworthy that the CD8 − CD11b + ESAM + DC subset that depends on Notch 2 signalling is localized to the splenic marginal zone in close proximity to stromal cells expressing DLL1 (REF. 42 ). As MZB cell development in the spleen is strictly dependent on DLL1-expressing stromal cells 33 it is tempting to speculate that splenic DC development is likewise dependent on DLL1.
In addition to splenic DCs, a subset of DCs located in the lamina propria of the intestine is strongly reduced in the absence of Notch 2. These DCs have a CD103 + CD11b + phenotype and are believed to be specialized in antigen capture and transport to the mesenteric lymph nodes, where they can activate CD4 + helper T cells, and in particular those secreting interleukin-17 (IL-17): that is, T helper 17 (T H 17) cells. Consistent with this model, T H 17 cell numbers are also decreased in the intestine following DC-specific conditional inactivation of Notch 2 (REF. 43 ). Taken together, these recent studies reveal a novel and tissue-specific role for Notch 2 in the homeostasis of distinct DC subsets and consequent control of T cell priming (FIG. 1) .
Notch signalling in innate lymphoid cell development.
More recently, the development of another set of interesting immune cells, the innate lymphoid cells (ILCs), was reported to be influenced by Notch signalling. ILCs encompass a novel family of haematopoietic effector cells that have important functions in innate immune responses to infectious microorganisms, in the generation of secondary lymphoid organs and in tissue remodelling after tissue injury or infection. ILCs develop from common lymphoid progenitors, but unlike B cells and T cells they do not rearrange immunoglobulin genes or express antigen-specific receptors. In general they can be subdivided in three major subclasses (group 1, group 2 and group 3 ILCs), depending on whether they express T H 1-type, T H 2-type or T H 17-type cytokines, respectively 46, 47 . Whereas natural killer (NK) cells, which belong to the group 1 ILCs, have cytotoxic activity and functions, lymphoid tissue-inducer (LTi) cells (a type of group 3 ILC) are essential for the development and generation of secondary lymphoid organs. LTi cell development is dependent on retinoid-related orphan receptor-γt (RORγt) 48 . In this context, Notch signalling was shown to be transiently required for the generation of fetal α4β7 + LTi cell progenitors before upregulation of RORγt. Subsequently, Notch signalling must be downregulated again to allow the expression of RORγt and the final maturation of LTi cells 49 . More recent additions to the RORγt-dependent group 3 ILC subclass are IL-22-producing ILCs, which have been referred to as ILC22s and which share hallmarks of LTi cells and NK cells. The ILC22s are noncytotoxic but express the NK marker NKp46 and produce high levels of IL-22, and are therefore also known as NK22 cells. They are mostly found in mucosal tissues (such as the lamina propria of the intestine, Peyer's patches or tonsils) in humans and mice, where they induce early protective immune responses to colitis-inducing pathogens 50, 51 . Both human and mouse ILC22s express the transcription factor aryl hydrocarbon receptor (AHR), which becomes activated by xenobiotics (that is, chemical compounds that are found in an organism but that are not normally produced by it, such as polycyclic aromatic compounds). On activation and ligand binding, AHR translocates from the cytoplasm to the nucleus and binds to promoter regions containing so-called xeno biotic response elements in order to induce target gene expression. 52, 53 , suggesting that the development and/or expansion of NKp46 + ILCs in certain microenvironments is mediated by AHR-induced Notch signalling 54 . Another RORγt-dependent but NKp46-negative subset of ILCs is mostly found in the colon of mice during inflammation. These cells express high levels of IL-17 in response to IL-23, which is responsible for gut pathology 55 . Whether this particular subset of ILCs is also dependent on Notch is currently unknown.
Nuocytes, which are also known as ILC2s because of their ability to secrete high levels of type 2 cytokines, including IL-5 and IL-13, are RORα-dependent cells. They proliferate in response to IL-25 and IL-33 administration or in response to pathogens, including parasitic helminths, viruses and fungi [56] [57] [58] . They have an important role in type 2-mediated immunity. For example, activation of these cells by the administration of IL-25 is sufficient to clear parasitic worms even in the absence of adaptive immunity 57 . In vivo, common lymphoid progenitor (CLP) reconstitution assays revealed that nuocytes are derived from CLPs in the bone marrow. However, they can also be generated in vitro under appropriate culture conditions. CLPs, along with DN1 and DN2 thymocytes, develop into nuocytes when cultured on DLL1-expressing OP-9 cells in the presence of IL-7 and IL-33. In the absence of DLL1-mediated Notch signalling, these progenitors develop into B cells, suggesting that Notch signalling is required at least for the in vitro generation of nuocytes. It remains to be investigated whether the in vivo development or expansion of these cells is also dependent on or influenced by Notch signalling. Although DN1 and DN2 thymocytes retain the potential to develop into nuocytes in vitro, forkhead box N1 (FOXN1) nu/nu mice (which lack a thymus) have normal nuocyte numbers; this indicates that in vivo these cells are likely to develop at extrathymic sites, such as the bone marrow 58 . Taken together, these studies reveal that Notch signalling can influence the development and/or expansion of certain subsets of ILCs, which is probably also microenvironment dependent (FIG. 2) . Future studies will be necessary to more specifically address the in vivo requirements and specific receptor-ligand interactions that are necessary for the development and function of certain ILC subsets. 65, 66 . Although these T H cell subsets were long thought to be fixed lineages, some plasticity in the pattern of cytokines that they secrete may occur during the course of infection, a process that would allow a specific T H cell subset to react to changing environmental conditions 67, 68 . Among the several factors contributing to the differentiation of naive CD4 + T cells towards a given T H cell subset, accumulating data indicate a crucial role for Notch signalling. However, the mechanisms involved have been somewhat controversial [69] [70] [71] . We discuss below recent advances in our understanding of the role for Notch in the differentiation and/or function of CD4 + T H cells. subsets. Studies carried out both in vitro and in vivo convincingly showed that the engagement of Delta-like Notch ligands favours the development of interferon-γ (IFNγ)-secreting T H 1 cells, whereas the engagement of Jagged ligands preferentially induces the development of T H 2 cells and T Reg cells (reviewed in detail in REFS 71, 73) . The type of Notch ligands involved in the differentiation of other T H cell populations awaits further studies.
Notch and helper T cell functions

Role of Notch ligands in
The impact of Notch on T H 1 cell function in vivo.
The impact of Notch receptor triggering on T H cell differentiation or function was first investigated using well-defined in vitro T H cell polarization conditions.
The numerous studies performed did not provide conclusive evidence for a role for Notch signalling during T H cell differentiation 69, 71 . The importance of Notch signalling on T H cell differentiation or function is better documented by an increasing number of studies carried out in vivo.
The role of Notch in the differentiation of IFNγ-secreting T H 1 cells in vivo has been investigated using several approaches designed to inhibit Notch signalling. Treatment of mice with γ-secretase inhibitors impeded disease progression in T H 1 cell-mediated experimental autoimmune encephalomyelytis (EAE) 74, 75 . It was hypothesized that Notch 1 could bind to an RBPJ-binding sequence on the T-box 21 (Tbx21) gene promoter, which encodes T-bet, the master regulator of T H 1 cell differentiation 74 ; however, such binding of Notch to the Tbx21 gene was not confirmed in another study 76 . Targeting γ-secretase may not only affect Notch cleavage but may also affect the cleavage of many other targets that could affect T H cell differentiation independently of Notch signalling, emphasizing the importance of using various experimental approaches to block Notch signalling. In contrast to the results obtained following γ-secretase treatment, functional T H 1 cells could develop in response to infection in mice that do not activate RBPJ because of dominant-negative MAML expression 77 . In the same line, mice deficient for RBPJ expression in their T cells were also able to mount a protective T H 1 cell response following infection with the parasite Leishmania major 78 . Altogether, these studies suggest that T H 1 cell differentiation does not involve canonical Notch signalling, defined as the association of the Notch intracellular domain (NICD) with RBPJ in the nucleus. Several partners could interact with Notch during non-canonical signalling in peripheral T cells. Subunits of the NF-κB transcription factor were identified as potential Notch partners 79, 80 , and further research is needed to characterize the interactions of Notch with NF-κB (FIG. 3a) .
To further study the impact of Notch on T H cell differentiation, Notch receptors were inactivated by genetic deletion in T cells or were blocked using monoclonal antibodies directed against Notch 1 or Notch 3. In a model of passively transferred EAE, the adoptive transfer of lymph node cells treated with Notch 3-specific neutralizing antibodies, but not with Notch 1-specific neutralizing antibodies, reduced the release of IFNγ and IL-17 by myelin-reactive cells, with a corresponding decrease in the EAE disease scores 75 . Of note, it was not possible to determine in this study whether the lower levels of IFNγ produced resulted from impaired T H 1 cell differentiation and/or from impaired T H 1 cell function. (FIG. 3a) . These data suggest that Notch signalling is involved in the control of T H 1 cell effector functions, rather than in the differentiation of T H 1 cells. Thus, Notch 1, Notch 2 and Notch 3 have each been individually shown to affect the functions of T H 1 cells in vivo, and it is possible that different Notch receptors may be involved in different T H 1-type contexts.
The impact of Notch on T H 2 cell differentiation in vivo.
Regulation of T H 2 cell differentiation in vivo by Notch was documented in several experimental models 81, 82 .
In contrast to what was reported in T H 1 cell differentiation, Notch signalling in T H 2 cell differentiation was shown to be dependent on RBPJ (canonical Notch signalling). Several RBPJ-binding sites were identified on the Il4 enhancer (conserved non-coding sequence 2 (CNS2); also known as HS5), suggesting a direct role of Notch in IL-4 transcription in T H 2 cells, NKT cells and possibly other IL-4-secreting cells 72, 82 . As IL-4 is a master regulator of T H 2 cell differentiation, Notch signalling may thereby promote T H 2 cell differentiation by both cell-intrinsic and cell-extrinsic mechanisms. In addition to its direct regulation of Il4, Notch was reported to bind to the promoter of GATA-binding factor 3 (GATA3), a master regulator of T H 2 cell differentiation 83 , thus inducing the expression of the Gata3 exon 1a transcript 83 . Both Notch 1 and RBPJ were shown to bind close to the Gata3 promoter, and GATA3 activity was required for the Notch-dependent induction of IL-4, suggesting a synergy between both pathways 76, 81 . Expression of GATA3 from the exon 1b transcript was shown to be independent of Notch. The conditions determining the selective usage of either GATA3 exon 1a or exon 1b transcripts and the need for Notch in T H 2 cell differentiation remain to be defined and are likely to be context dependent (FIG. 3b) .
The impact of Notch on other T H cell subsets in vivo.
The Notch signalling pathway was also shown to cooperate with TGFβ to induce T H 9 cells 84 . Interaction between SMAD3, a TGFβ target protein, and RBPJ resulted in the induction of the IL-9 promoter. Mice deficient in Notch 1 and Notch 2 in their T cells developed milder EAE compared with control mice, and both IL-9 and IL-17 cytokine production was decreased upon antigenic re-stimulation in vitro. This suggested that Notch signalling is regulating T H 9 cell function during EAE. However, although the impact of Notch signalling on EAE is well documented, it is difficult to evaluate the impact of Notch on individual T H subsets during EAE owing to the plasticity among T H subsets (T H 17, T H 1, T H 9 and T Reg cells) that develops during the disease 85 . Altogether, increasing evidence reveals that Notch signalling considerably influences the development of immune responses by acting on the differentiation or function of different T H subsets (FIG. 3) . Better understanding of the mechanisms involved in these processes will allow the design of appropriate strategies to favour or prevent the development of a T H cell subset during pathologies in which these T cells have important roles. . Further studies by this group reported that Notch 3 promoted the development of T Reg cells and improved their suppressive activity by upregulating FOXP3 expression 88, 89 . In a more physiological setting, T Reg cell exposure to Jagged 2-expressing haematopoietic progenitors induced the activation of Notch 3 signalling and promoted the expansion of T Reg cells that could prevent disease onset in an experimental type 1 diabetes model 90 . Collectively, these studies indicate an important role for Notch signalling in the expansion of T Reg cells. Neutralization of DLL4 during the induction of EAE resulted in an increase in the number of peripherally induced T Reg cells with a corresponding decrease in disease severity 91 . The effect was specific to DLL4, as DLL1 blockade had no effect on T H 17 and T Reg cell differentiation during EAE 92 . In addition, a more recent study showed that anti-DLL4 treatment prevented the development of, and even reverted, type 1 diabetes in nonobese diabetic (NOD) mice by inducing an increase in the number of DC-dependent de novo thymic T Reg cells 93 . Taken together, these results demonstrate an essential role for DLL4-mediated immune regulation in the control of both thymic T Reg cell and peripherally induced T Reg cell homeostasis, although mechanistic details remain to be elucidated. Blocking Notch ligands could be a strategy to selectively regulate T Reg cell proliferation. Increasing data suggest that the selective blocking of DLL4-mediated Notch signalling ameliorates multiple forms of experimental autoimmunity via the regulation of T Reg cells
Notch and regulatory T cell functions
.
Jagged-mediated Notch signalling is also important in the control of peripherally induced T Reg cell differentiation. TGFβ induces FOXP3 expression in peripheral naive T cells, allowing their differentiation into peripherally induced T Reg cells 62, 94 . A role for Notch signalling in peripherally induced T Reg cell differentiation was first suggested by several experiments showing that overexpression of the Notch ligand Jagged 1 on APCs led to peripherally induced T Reg cell differentiation both in vitro and in vivo 95, 96 . The peripheral induction of T Reg cells by Notch signalling was shown to involve the activation of FOXP3, the master transcription factor of T Reg cells. Notch 1 co operates with SMAD3 (a mediator of TGFβ signalling) and RBPJ to activate FOXP3 transcription 5, 97 . Accordingly, in vivo treatment of mice with γ-secretase inhibitors reduced the TGFβ-mediated induction of FOXP3, decreased peripherally induced T Reg cell development and maintenance, and led to the development of auto immune hepatitis 5 . The importance of Notch signalling in ensuring sustained FOXP3 expression and maintenance of peripherally induced T Reg cells was recently confirmed in human cells 98 . Pluripotent stem cells transduced with FOXP3 and co-cultured on Notch ligandexpressing stromal cells generated stable T Reg cells in vitro 99 , suggesting that this could be a strategy for producing stable T Reg cells for therapeutic adoptive transfer.
Collectively, increasing experimental evidence demonstrates a crucial role for Notch signalling in the expansion of thymic T Reg cells, in the differentiation of peripherally induced T Reg cells and in the maintenance of both of these T Reg cell populations. However, more direct loss-of-function experiments will be required to validate these conclusions. In addition, CD8 + T cells exposed to allogenic DCs transduced with DLL1 showed increased granzyme B production and lysed target cells more efficiently in vitro, suggesting that DLL1-induced signalling contributes to CTL differentiation in vivo 101 . DLL1 blockade similarly decreased the frequency of granzyme B-producing CTLs, and lower cytotoxic activity of CD8 + T cells was observed in a transplantation model 102 . Notch 2 expression on CD8 + T cells was reported to promote CTL differentiation and to directly regulate granzyme B and perforin expression both in vitro and in vivo, demonstrating a crucial role for Notch signalling in CD8 + T cell cytotoxic responses. Notch 2 formed a complex with phosphorylated cyclic AMP-responsive element-binding protein 1 (pCREB1) and the transcriptional co-activator p300 on the granzyme B (Gzmb) promoter 101 . The same group later reported that Notch 2 signalling, but not Notch 1 signalling, was required for the generation of antitumour CTL responses 103 . Further indication for a role of Notch signalling in CTL effector functions was reported using γ-secretase inhibitor treatment, which blocked the expression of the T-box eomesodermin (EOMES) transcriptional factor, thus reducing perforin and granzyme B expression.
Notch, cytotoxic T cells and GVHD
Box 2 | Notch and autoimmune disease
Autoimmune diseases such as multiple sclerosis and type 1 diabetes arise from inappropriate immune responses against self antigens, leading to the selective destruction of particular cell types or tissues. These inappropriate immune responses involve both adaptive and innate immune cells. As Notch signalling is involved in the regulation of peripheral immune responses, multiple groups have investigated the outcome of manipulating Notch signalling in experimental autoimmune disorders. Experimental autoimmune encephalomyelitis (EAE) is a frequently used mouse model for multiple sclerosis 117 . This inflammation-mediated demyelination disease of the central nervous system (CNS) can be induced by immunization with myelin antigens, viral infection or transfer of autoreactive T cells. Genetic and pharmacological interference with Notch signalling, as well as administration of blocking antibodies against Notch receptors or Delta-like ligand 4 (DLL4), impeded progression of the disease, resulting in reduced clinical severity 74, 75, 84, 91, 92, [118] [119] . The mechanisms by which blockage of Notch signalling ameliorates EAE are not fully understood and require further investigation. Possibilities include impaired T helper 1 (T H 1)-type and T H 17-type immune responses 91 ; impaired migration of antigen-specific CD4 + T cells to the CNS as a consequence of downregulation of chemokine receptors 119 ; and/or promotion of regulatory T cell development 91 . Similar observations have been reported in a more recent study using non-obese diabetic (NOD) mice as a model for type 1 diabetes. In these mice, pancreatic β-cells are selectively destroyed through autoreactive T cells. Administration of DLL4-specific antibodies prevented the development of type 1 diabetes and in some cases even caused the reversion of already established disease by inducing de novo expansion of regulatory T cells 93 . Taken together, these preclinical studies indicate that selective blocking of DLL4-mediated Notch signalling may ameliorate multiple forms of autoimmunity.
Treatment with γ-secretase inhibitors did not affect the FAS-FASL interactions of CTLs. Notch 1 antisense (Notch1 AS) mice, which have reduced expression of Notch 1, also showed reduced EOMES, perforin and granzyme B expression, suggesting that Notch 1 signalling is involved in CTL differentiation 104 . The nature of the Notch receptor involved (Notch 1 or Notch 2) may vary depending on the experimental context. A recent study reported a role for Notch also in the generation and function of human CD8 + T cells, suggesting that its role in this particular subset of T cells is conserved 105 . Collectively, these experiments show an important role for Notch signalling in the differentiation of functional CTLs. The implication of Notch signalling in the generation of memory CD8 + T cells has not been investigated yet and should be of interest.
Notch signalling in GVHD.
More recent evidence also suggests a role for the Notch cascade in regulating graftversus-host disease (GVHD) following allogeneic bone marrow transplantation (allo-BMT). Patients with leukaemia and patients with lymphoma have to undergo allo-BMT in cases in which tumour cells cannot be eradicated by chemotherapy. The goal of allo-BMT is that transplanted donor T cells mediate graft-versus-tumour (GVT) activity and thereby kill the cancer cells. However, GVT activity is often associated with GVHD because donor T cells also react against normal host tissue. This represents one of the major complications of allo-BMT in patients with cancer. Although these patients can subsequently be treated with immunosuppressive drugs to decrease the risk of GVHD, it comes at the price of impairing GVT activity. Such patients have a higher risk of undergoing tumour relapse, which compromises their overall survival 106 . In this context, preclinical studies were used to evaluate the function of Notch signalling in T cells in mouse models of allo-BMT settings using genetic loss-offunction approaches. Expression of a dominant-negative form of MAML1 (which blocks canonical Notch signalling of all receptors) in donor T cells resulted in near complete protection from acute GVHD in multiple models of allo-BMT (including major antigen mismatched models, such as transplantation of C57Bl/6 bone marrow into BALB/c hosts). More importantly, these Notch signalling-incompetent T cells retained cytotoxic and anti-leukaemic activity, leading to substantially improved overall survival of host animals challenged with a B cell-lineage lymphoma. The protection against GVHD in this experimental setting was not mediated by an overall immunosuppression, as the Notch-deficient alloreactive T cells exhibited normal in vivo proliferative responses 107 . However, T cells expressing the dominantnegative-MAML1 mutant or lacking RBPJ produced reduced levels of multiple inflammatory cytokines, including IFNγ, IL-4, IL-17, tumour necrosis factor and IL-2, compared with wild-type T cells. Interestingly, the levels of T-bet and EOMES, which are, respectively, master regulators of T H 1 cell and effector CD8 + T cell differentiation, were unchanged in Notch signalling-deficient T cells 107 . This argues against a simple differentiation defect of helper or effector T cells as a consequence of loss of Notch signalling. A more recent study from the same group in which blocking antibodies were used revealed that the beneficial effect of inhibiting Notch signalling in models of GVHD is mediated via the specific blockade of Notch 1 and Notch 2 on the receptor side and DLL1 and DLL4 on the ligand side. Blockage of individual receptors and ligands revealed dominant effects for Notch 1 and DLL4. Importantly, the combined administration of DLL1-specific and DLL4-specific antibodies provided long-lasting protection against GVHD without any apparent gut toxicities, such as those observed using blocking antibodies against the Notch receptors. The protection correlated with the persistent expansion of T Reg cells 108 . Although the elucidation of the precise mechanism requires further investigation, the impressive effects of blocking Notch signalling in mouse models of GVHD indicate a strong potential for clinical translation.
In addition to the role of Notch in alloreactive T cells, recent work suggests that Notch signalling in DCs can also influence GVHD 109 . Ikaros is a transcriptional repressor that in some contexts functions as a negative regulator of Notch signalling 110, 111 . Ikaros-deficient bone marrow chimaeras revealed an enhanced GVHD in multiple models of allo-BMT compared with control animals. Ikaros deficiency resulted in upregulation of multiple Notch receptors, ligands and Notch target genes in DCs. Allogeneic T cells proliferated more when co-cultured with Ikaros-deficient DCs compared with when they were co-cultured with wild-type DCs, but this increased proliferation was reverted following the treatment of T cells with γ-secretase inhibitors to block Notch signalling. More importantly, allogeneic Ikaros-deficient bone marrow chimaeras treated with γ-secretase inhibitors in vivo showed a significantly diminished GVHD pathology compared with vehicle-treated control chimaeras 109 . It remains to be investigated whether Notch signalling in wild-type DCs influences GVHD. However, taken together, these reports show that blocking Notch signalling ameliorates GVHD in allo-BMT models, whereas GVT activity is preserved.
Conclusion and perspectives
During the past decade the Notch cascade has emerged as an important regulator of multiple cell fate decisions and differentiation processes during the development and function of the haematopoietic system. Among the most well-established functions of Notch are its essential roles in the specification and maturation of T cells, as well as of MZB cells. For these two lymphoid lineages, the relevant receptor-ligand pairs have been identified by conditional genetic loss-of-function approaches. T cell lineage commitment and maturation is mediated by DLL4-Notch 1 interactions, and MZB cell development is mediated by DLL1-Notch 2 interactions. Both of these processes use canonical (that is, RBPJ-dependent) Notch signalling. More recently, a role for Notch during development and/or expansion of ILCs has been identified. The role of Notch in ILCs has been inferred from multiple studies through the requirement of DLL-expressing feeder cells to generate ILCs in vitro. However, conditional inactivation of RBPJ has clearly demonstrated that Notch signalling is required in vivo for the development and/or expansion of NKp46 + ILCs within the lamina propria of the intestine. Additional loss-of-function studies will be required in the future to establish the in vivo relevance of Notch in ILCs, as well as for elucidating the ligand-receptor interactions that are involved.
Genetic loss-of-function experiments also show an important role of Notch signalling in both T H 2 cell differentiation and T H 1 cell function. Experimentally, Jagged or DLL expression on APCs has been associated with T H 2 cell and T H 1 cell differentiation, respectively. Genetic, pharmacological and antibody-based blockage of specific ligands and receptors confirmed the role of DLL-mediated Notch signalling in T H 1 cell function. Interestingly, this is a process that does not require canonical RBPJ-mediated signalling. By contrast, T H 2 cell differentiation is dependent on canonical Notch signalling. It is still generally unknown how Jagged-and DLL-expressing APCs differ in their ability to induce Notch signals and how this translates into the differentiation of T H cells.
Pharmacological Notch inhibitors and more specific blocking antibodies for individual Notch receptors and ligands were originally developed for anticancer therapy. These tools are now also being explored in the context of preclinical investigations of autoimmune diseases and GVHD. In particular, blocking Notch using DLL4-specific antibodies ameliorated pathology in several experimental autoimmune disease models. Similarly, Notch blockade in allo-BMT significantly reduced GVHD while preserving GVT activity. Although the exact mechanisms underlying these promising observations are not clear, they open the door to exploring these tools in immunological disorders in a clinical setting. Thus, Notch is an attractive target not only for cancer therapy but also for modulating the immune system during other pathological conditions.
